Pfizer's ($PFE) collaboration with Antares Pharma, using the latter's drug delivery technology to deliver an undisclosed consumer healthcare product, has hit a development milestone, delivering a $750,000 payment to Antares. The company has already received an upfront payment from the agreement, announced in December 2011, which gives Pfizer exclusive rights in North America. But we are still getting no clues as to the drug or the delivery technology, other than a hint from Paul K Wotton, president and CEO of Antares, that it "targets a significant therapeutic area." Watch and wait. Press release